Abstract

Cross-reactive vaccines recognize common molecular patterns in pathogens and are able to confer broad spectrum protection against different infections. Antigens common to pathogenic bacteria that induce broad immune responses, such as the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) of the genera Listeria, Mycobacterium, or Streptococcus, whose sequences present more than 95% homology at the N-terminal GAPDH1−22 peptide, are putative candidates for universal vaccines. Here, we explore vaccine formulations based on dendritic cells (DC) loaded with two molecular forms of Listeria monocytogenes GAPDH (LM-GAPDH), such as mRNA carriers or recombinant proteins, and compare them with the same molecular forms of three other antigens used in experimental vaccines, listeriolysin O of Listeria monocytogeness, Ag85A of Mycobacterium marinum, and pneumolysin of Streptococcus pneumoniae. DC loaded with LM-GAPDH recombinant proteins proved to be the safest and most immunogenic vaccine vectors, followed by mRNA encoding LM-GAPDH conjugated to lipid carriers. In addition, macrophages lacked sufficient safety as vaccines for all LM-GAPDH molecular forms. The ability of DC loaded with LM-GAPDH recombinant proteins to induce non-specific DC activation explains their adjuvant potency and their capacity to trigger strong CD4+ and CD8+ T cell responses explains their high immunogenicity. Moreover, their capacity to confer protection in vaccinated mice against challenges with L. monocytogenes, M. marinum, or S. pneumoniae validated their efficiency as cross-reactive vaccines. Cross-protection appears to involve the induction of high percentages of GAPDH1−22 specific CD4+ and CD8+ T cells stained for intracellular IFN-γ, and significant levels of peptide-specific antibodies in vaccinated mice. We concluded that DC vaccines loaded with L. monocytogenes GAPDH recombinant proteins are cross-reactive vaccines that seem to be valuable tools in adult vaccination against Listeria, Mycobacterium, and Streptococcus taxonomic groups.

Highlights

  • Vaccines for adults is one of the biggest challenges of current vaccinology and several methodologies have been proposed for this purpose such as reverse vaccinology, a genome-based approach to vaccine development [1], or immune algorithm approaches [2,3,4]

  • We focused our study to L. monocytogenes glyceraldehyde-3-phosphage dehydrogenases (GAPDH) antigen (Lmo2459) since it presents similar ADP-ribosylating abilities, immunogenic domains, and cross-immune responses in three bacterial genera of our study, Listeria, Mycobacterium, and Streptococcus [24,25,26, 28]

  • Listeria monocytogenes GAPDH in two forms, either as a recombinant protein or as an Messenger RNA (mRNA)-GNP complex, appears to be a safe bacterial antigen that induce significant T cell mediated immune responses when used in Dendritic cells (DC) vaccine vectors

Read more

Summary

Introduction

Vaccines for adults is one of the biggest challenges of current vaccinology and several methodologies have been proposed for this purpose such as reverse vaccinology, a genome-based approach to vaccine development [1], or immune algorithm approaches [2,3,4]. One of the main issues regarding vaccines for adults is the possibility to prepare bacterial vaccines that induce cross-protection against infections caused by different pathogens that provide cellular specific immunity, involving both T and B cells, known as cross-reactive vaccines (CRV). Cross-protection against infections can be achieved if innate immune cells acquire long functional states such as in trained immunity-based vaccines (TIbV) [5]. Dendritic cells (DC) are pivotal cells for conventional, CRV, or TIbV vaccines and serve as efficient vaccine platforms. In this regard, DC based vaccines can recognize non-specific patterns in pathogens and can induce specific immunity [5,6,7], allowing cross-protection against infections. The COVID-19 pandemic has highlighted the possibility that vaccines designed for unrelated pathogens such as Mycobacterium bovis Bacillus Calmette-Guérin (BCG), could confer some protection for a coronavirus [8, 9]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call